Western European Journal of Medicine and Medical Science
Volume 4, Issue 06, June 2026
https://westerneuropeanstudies.com/index.php/3
ISSN (E): 2942-1918 Open Access| Peer Reviewed

DECIPHERING THE MECHANOBIOLOGICAL AND IMMUNOLOGICAL PATHWAYS OF BIOPROSTHETIC HEART VALVE CALCIFICATION: THE DAWN OF NEXT GENERATION SMART BIO SCAFFOLDS .

Kakhorova Karomatkhon Sovronbayevna, Lecture of General Medical sciences of Medical Faculty NamSU
Kurbonova Madinabonu Shukhrat kizi 1st year student of Medical Faculty NamSU
Jurayeva Mukhtasar Ilyosovna 1st year student of Medical Faculty NamSU

Abstract
Background: Bioprosthetic heart valves (BHVs) remain the gold standard for valvular replacement; however, their clinical longevity is strictly compromised by structural valve degeneration (SVD), primarily driven by accelerated calcification. While mechanical stresses are recognized, the orchestrating molecular cascades and the specific cellular cross-talk at the graft-host interface remain fully elucidated.
Objective: This review provides a comprehensive molecular-biomedical synthesis of BHV calcification pathology, specifically focusing on the intersection of immunogenicity and mechanobiology, while evaluating translatable next-generation bio-scaffold solutions.
Methods/Main focus of analysis: We dissect the precise roles of chronic foreign body response (FBR) and macrophage M1/M2 polarization dynamics that drive the osteogenic transdifferentiation of valvular interstitial cells (VICs). Particular emphasis is placed on the aberrant activation of the Wnt/β-catenin and RANK/RANKL/OPG signaling pathways, and the critical regulatory disruption of the Notch1 cascade. Furthermore, we critically evaluate current technological shifts in tissue engineering, specifically looking at multi-locus CRISPR-Cas9 gene-editing for xenografts and the deployment of cell-free smart biomimetic scaffolds.
Conclusion: Overcoming SVD requires transitioning from inert bioprostheses to dynamic, immunotolerant bio-scaffolds. Bridging the translational gap between benchtop tissue engineering and the cardiothoracic operating theater is paramount to achieving the ultimate goal: a living, regenerative valve substitute.

1. Introduction
For over half a century, the evolution of cardiovascular surgery has been fundamentally intertwined with the development of prosthetic heart valves. In the contemporary clinical landscape, when surgical intervention becomes unavoidable for terminal valvular pathologies—such as critical aortic stenosis or advanced insufficiency—surgeons are faced with a classic, yet increasingly complex dichotomy: mechanical versus bioprosthetic heart valves (BHVs). Mechanical valves offer outstanding structural durability but condemn the recipient to lifelong, systemic anticoagulation therapy, carrying persistent risks of major hemorrhagic events and thromboembolism. Consequently, the global paradigm has shifted dramatically toward the utilization of BHVs, manufactured from glutaraldehyde-fixed porcine aortic valves or bovine pericardia, which provide superior hemodynamics and eliminate the necessity for aggressive anticoagulation.

Western European Journal of Medicine and Medical Science
Volume 4, Issue 06, June 2026
https://westerneuropeanstudies.com/index.php/3
ISSN (E): 2942-1918 Open Access| Peer Reviewed

However, the undeniable short-to-medium-term clinical success of BHVs is severely undermined by a definitive and progressive biological barrier: Structural Valve Degeneration (SVD). SVD is an insidious process characterized by the loss of leaflet pliability, tearing, and functional failure, with accelerated dystrophic calcification serving as its primary pathological hallmark. Within 10 to 15 years post-implantation, more than 30% of bioprostheses in patients over 65 require redo surgical interventions, a statistic that escalates catastrophically to nearly 50% in younger recipients due to their more active calcium metabolism and robust immune systems. For a geriatric patient or an individual undergoing a complex re-operation, a secondary open-heart procedure carries unacceptable morbidity and mortality rates.

While historical paradigms categorized BHV calcification as a passive, purely chemical precipitation of calcium phosphate crystals onto dying donor cells, modern medical biology has shattered this oversimplified dogma. SVD is now recognized as an active, highly regulated, cell-mediated pathological process driven by a complex interplay between chronic immune responses and altered mechanical shear stress. The residual immunogenicity of the graft, compounded by the cytotoxicity of glutaraldehyde cross-linking, triggers a chronic foreign body response. This persistent inflammatory microenvironment forces host cells to execute a pathobiological transition, ultimately leading to the osteogenic transdifferentiation of valvular interstitial cells (VICs).

Despite extensive research, a critical translational gap persists. Cardiothoracic surgeons routinely witness the macro-level catastrophic failures of these biomaterials in the operating theater, while molecular biologists uncover micro-level signaling pathways in isolated laboratory environments. Yet, a cohesive synthesis that bridges these two domains remains scarce. This review aims to bridge this exact chasm. By dissecting the precise molecular and immunobiological axes of BHV calcification—specifically focusing on macrophage polarization and aberrant osteogenic signaling cascades—we provide a comprehensive analysis of why current bioprostheses fail. Furthermore, we evaluate how next-generation tissue engineering, including multi-locus CRISPR-Cas9 gene editing and smart, cell-free biomimetic scaffolds, can finally transition the field from installing inert, degrading plastics and dead tissues into implanting living, self-regenerating valvular constructs.

2. Molecular and Immunological Mechanisms of Calcification

The degeneration of bioprosthetic heart valves (BHVs) is not merely an accumulation of mineral deposits, but an active, highly orchestrated pathological recapitulation of osteogenesis. This process unfolds at the intersection of a chronic immunological cascade and aberrant intracellular signaling within host and donor cells.

2.1. The Foreign Body Response and Macrophage Polarization Dynamics

Immediately following surgical implantation, the host immune system recognizes the BHV as a major immunogenic challenge. Despite decellularization and glutaraldehyde (GA) cross-linking, remnant donor antigens—most notably **Galactose-α-1,3-galactose (α-gal)**—and exposed extracellular matrix (ECM) proteins trigger the immediate adsorption of host plasma proteins. This protein corona incites the recruitment of circulating monocytes, which rapidly differentiate into **M1 macrophages** (pro-inflammatory phenotype).

Under physiological tissue healing conditions, a phenotypic switch from M1 to **M2 macrophages** (pro-resolving/tissue-remodeling phenotype) occurs to restore homeostasis. However, within the BHV microenvironment, this switch is permanently disrupted. The continuous mechanical shear stress of the cardiac cycle, combined with the cytotoxicity of residual GA, locks the local immune response into a chronic M1-dominant state. These

Western European Journal of Medicine and Medical Science
Volume 4, Issue 06, June 2026
https://westerneuropeanstudies.com/index.php/3
ISSN (E): 2942-1918 Open Access| Peer Reviewed

persistent M1 macrophages secrete high concentrations of pro-inflammatory cytokines, including:

Tumor Necrosis Factor-alpha (TNF-α)
Interleukin-1 beta (IL-1β)
Interleukin-6 (IL-6)

These cytokines act as potent paracrine signals that stimulate adjacent host valvular interstitial cells (VICs) and circulating mesenchymal stem cells, driving them toward a pathological lineage.

2.2. Aberrant Signaling Pathways and Osteogenic Transdifferentiation

The chronic inflammatory milieu triggers a profound phenotypic transition of Valvular Interstitial Cells from a quiescent, fibroblast-like state (qVIC) into a pathological, bone-forming osteoblast-like phenotype (obVIC). This transdifferentiation is governed by three interconnected molecular axes:

1. **The Wnt/β-catenin Pathway:** Inflammatory cytokines activate the canonical Wnt signaling cascade. Upon Wnt ligand binding to Frizzled receptors,β-catenin degradation is inhibited, allowing it to accumulate in the cytoplasm and translocate into the nucleus. Here, it upregulates **Runx2 (Runt-related transcription factor 2)**, the master regulator of osteogenesis.
2. **The Notch1 Regulatory Disruption:** Under healthy conditions, intact Notch1 signaling acts as a critical molecular brake, suppressing osteogenic differentiation in valvular tissue. Genetic mutations or inflammatory suppression of Notch1 relieve this inhibition, directly accelerating the expression of osteogenic downstream targets like **Osterix (Osx)** and **Alkaline Phosphatase (ALP)**.
3. **The RANK/RANKL/OPG Axis:** M1 macrophages and stressed VICs secrete Receptor Activator of Nuclear Factor κB Ligand (**RANKL**). When RANKL binds to its receptor RANK on target cells, it overwhelms the protective effects of Osteoprotegerin (**OPG**), a soluble decoy receptor. This imbalance promotes matrix vesicle release, facilitating the nucleation of **hydroxyapatite** **[$\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$]** crystals within the collagen extracellular matrix, ultimately leading to macroscopic leaflet solidification and stenosis.

3. Next-Generation Solutions: Tissue Engineering and CRISPR-Cas9

To overcome the inherent biological limitations of conventional bioprosthetic heart valves (BHVs), the paradigm of cardiovascular surgery must transition from installing inert, fixed matrices to fabricating living, immunotolerant, and self-regenerative constructs.

3.1. Multi-Locus CRISPR-Cas9 Gene Editing for Xenotransplantation

The primary hurdle in porcine-derived xenografting is hyperacute and chronic immune rejection driven by species-specific surface antigens. Next-generation genetic engineering utilizes multi-locus CRISPR-Cas9 technology to systematically silence these immunogenic targets.

The α-Gal Knockout: The primary focus is the inactivation of the **α-1,3-galactosyltransferase (αGal)** gene, effectively eliminating the dominant epitope responsible for complement-mediated hyperacute rejection.

Beyond α-Gal: Current molecular approaches combine αGal deletion with the knockout of non-αGal antigens, such as **cytidine monophosphate N-acetylneuraminic acid hydroxylase (CMAH)** and **β1,4-N-acetylgalactosaminyltransferase 2 (B4GALNT2)**.

Western European Journal of Medicine and Medical Science
Volume 4, Issue 06, June 2026
https://westerneuropeanstudies.com/index.php/3
ISSN (E): 2942-1918 Open Access| Peer Reviewed

Simultaneously, the transgenic knock-in of human complement regulatory proteins (e.g., **hCD46**, **hCD55**) into the donor porcine genome shields the endothelial lining from host membrane attack complex (MAC) assembly, establishing sustained immunotolerance without aggressive systemic immunosuppression.

3.2. Cell-Free Smart Biomimetic Scaffolds and In Situ Tissue Engineering

While in vitro tissue engineering—pre-seeding scaffolds with patient-derived stem cells—remains technologically elegant, its clinical translation is bottlenecked by astronomical costs, complex regulatory hurdles, and long manufacturing timelines. Thus, the field is pivoting toward **In Situ Tissue Engineering** using cell-free, smart biomimetic scaffolds.

This strategy relies on an acellular, decellularized extracellular matrix (dECM) or highly engineered electrospun synthetic polymers designed to recruit the host's own endogenous stem cells directly *in vivo*. The surface of these scaffolds is functionalized with specific bioactive molecules:

Sensing Microenvironment: Incorporating vascular endothelial growth factor (**VEGF**) mimics promotes rapid, homing host endothelization, sealing the biomaterial from circulating immune cells.

Controlling Macrophage Phenotype: The integration of specific microRNAs (e.g., **miR-146a** or **miR-223**) within the scaffold matrix actively forces infiltrating host monocytes to skip the pro-inflammatory M1 phase and polarize directly into the pro-healing **M2 phenotype**. By controlling the host immune system rather than fighting it, these smart scaffolds prevent osteogenic transdifferentiation, allowing the inert implant to gradually transform into a living, growing, and remodelling heart valve.

Discussion

The transition from understanding the molecular architecture of bioprosthetic heart valve (BHV) calcification to engineering a clinical solution represents one of the most formidable challenges in modern translational medicine. The findings synthesized in this review underscore a profound paradigm shift: BHV calcification is no longer viewed as an inevitable, passive physicochemical precipitation of calcium ions, but rather as an active, highly regulated, cell-mediated chronic inflammatory pathology.

4.1. The Translational Paradox of Tissue Engineering

The core conflict within contemporary cardiovascular research lies in what we define as the "Translational Paradox." Over the past decade, numerous *in vitro* studies have successfully fabricated tissue-engineered heart valves (TEHVs) by seeding synthetic or decellularized scaffolds with patient-derived bone marrow mesenchymal stem cells (BM-MSCs) or endothelial progenitor cells (EPCs). While these constructs demonstrate exceptional biomimetic characteristics and short-term hemodynamic stability in animal models, their transition to human clinical trials remains severely bottlenecked.

The underlying biological reason for this failure is the uncontrolled host immune response upon implantation. Pre-seeded cells often fail to survive the acute shear stress and immediate complement activation of human cardiopulmonary bypass. Once these cells undergo apoptosis, they paradoxically serve as nucleation sites for accelerated kalsifikatsiya, micro-embolization, and early structural valve degeneration (SVD). Therefore, the traditional paradigm of complex, high-cost *in vitro* cell seeding must be critically re-evaluated in favor of *in situ* guided tissue regeneration.

Western European Journal of Medicine and Medical Science
Volume 4, Issue 06, June 2026
https://westerneuropeanstudies.com/index.php/3
ISSN (E): 2942-1918 Open Access| Peer Reviewed

4.2. Deciphering the Immunological Gatekeepers: M1 vs. M2 Polarization

As detailed in our molecular synthesis, the fate of an implanted bio-scaffold is dictated within the first weeks by the polarization state of infiltrating host macrophages. The structural failure of current glutaraldehyde-fixed biomaterials stems from their inability to facilitate the crucial M1-to-M2 phenotypic transition. By maintaining a chronic M1-dominant pro-inflammatory microenvironment, these biomaterials continuously drive host valvular interstitial cells (VICs) toward the osteogenic lineage via the canonical Wnt/β-catenin and RANKL pathways.

Consequently, future therapeutic strategies must not aim for complete immunosuppression—which impairs physiological tissue remodeling—but rather for precise **immunomodulation**. Advanced bio-scaffolds functionalized with specific microRNAs (such as **miR-146a**) or coated with localized immunomodulatory cytokines (like **IL-10** or **TGF-β**) offer a highly promising frontier. By actively steering the host immune system to adopt a pro-healing M2 phenotype, we can theoretically suppress the activation of the osteogenic master regulator **Runx2**, thereby halting dystrophic calcification before macroscopic mineralization begins.

4.3. Clinical Limitations and Future Horizons

From a cardiothoracic surgeon's perspective, any next-generation valvular substitute must match or exceed the immediate mechanical reliability of current transcatheter aortic valve implantation (TAVI) and surgical bioprostheses. The clinical adoption of CRISPR-Cas9 multi-locus gene-edited xenografts represents a monumental leap forward, yet long-term durability data in human subjects remain scarce.

The ultimate horizon of cardiovascular surgery lies in the synthesis of material science and molecular biology: a cell-free, smart biomimetic scaffold that undergoes synchronized degradation as the host's endogenous cells infiltrate, proliferate, and remodel the matrix into a living, autologous heart valve. Bridging this translational gap requires sustained, cross-disciplinary collaboration between benchtop molecular biologists, polymer chemists, and cardiothoracic surgeons.

Conclusions and Future Perspectives

The paradigm of heart valve replacement is standing on the precipice of a profound biological revolution. For decades, cardiothoracic surgery has relied on the mechanical substitution of tissue—a strategy that successfully restores macro-hemodynamics but fails to address the micro-level host-graft biological incompatibility. As synthesized in this review, bioprosthetic heart valve calcification is not a passive chemical failure, but an active, cell-mediated osteogenic process driven by chronic M1 macrophage polarization and aberrant activation of the Wnt/β-catenin and Notch1 signaling pathways.

The future of the field belongs to therapies that do not fight the host immune system, but rather modulate it. The clinical realization of living, regenerative valve substitutes requires a dual-track strategy:

In the near term: The optimization of multi-locus CRISPR-Cas9 gene-edited xenografts to systematically eliminate non-human glycan antigens (α-gal, CMAH, B4GALNT2), providing immediate, low-immunogenicity off-the-shelf solutions for aging populations.

In the long term: The clinical translation of cell-free, smart biomimetic scaffolds capable of controlled *in situ* tissue engineering. These constructs will leverage endogenous cell homing and precise microRNA-driven M2 macrophage polarization to transition seamlessly from an inert implant into a living, autologous heart valve that grows and remodels with the patient.

To dismantle the persistent translational gap between the laboratory bench and the surgical theater, sustained cross-disciplinary synchronization between molecular biologists, material

Western European Journal of Medicine and Medical Science
Volume 4, Issue 06, June 2026
https://westerneuropeanstudies.com/index.php/3
ISSN (E): 2942-1918 Open Access| Peer Reviewed

scientists, and cardiothoracic surgeons is paramount. Only through this unified scientific lens can we finally transition from managing structural valve degeneration to curing it.